SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Spectral Diagnostics (DIAGF) Cardiac Diagnostics, Troponin
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Calvin Lee who wrote (3)5/16/1997 2:43:00 PM
From: Art Hampton   of 10
 
This info is from a friend who is a lab supervisor:

Spectral labs puts out this point of care device for the triage of
patients with rule out or rule myocardial infarction. I believe this
device may already be FDA approved. Anyway it is supposed to give
clinicians ckmb/myoglobin and troponin-I in 10 minutes. This is a joint
venture with DADE who owns the antibodies for the three assays. We do currently use the DADE stratus Intellect for performing the troponin-i assay.

Also BMC already has a point of care device for providing troponin-t
results very quickly. However, for those positive results, the vendor is
saying that it should be quantified by the lab method. Tropoinin-I is a
much more cardio specific assay than the BMC "T" assay.

I don't know if these point of care devices will be widely used since
their individual cost is so high (typically around 20-30 dollars per
device). These tests can be performed in the central lab much more cost effective.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News